Table 2. Primary Outcome.
| VA | NoVA | p value | |
|---|---|---|---|
| MMP1 (ng/mL) | 156 (111, 254) |
184 (97, 337) |
0.7 |
| MMP2 (mcg/mL) | 178 (168, 213) |
191 (182, 212) |
0.3 |
| MMP3 (mcg/mL) | 13 (6, 17) |
6 (4, 10) |
0.01 |
| MMP9 (mcg/mL) | 33 (24, 41) |
35 (28, 46) |
0.3 |
| TIMP1 (mcg/mL) | 74 (69, 81) |
68 (58, 77) |
0.1 |
| TIMP2 (mcg/mL) | 115 (101, 128) |
107 (91, 118) |
0.3 |
| TIMP4 (ng/mL) | 1339 (1132, 1642) |
1434 (1069, 1625) |
0.8 |
| CICP (ng/mL) | 10 (8, 16) |
14 (10, 21) |
0.06 |
Data reported as median with 25%, 75% range. Significance tested using Mann Whitney U test.
VA- history of serious ventricular arrhythmia, noVA- no history of serious ventricular arrhythmia, MMP- matrix metalloproteinase, TIMP- tissue inhibitor of metalloproteinase, CICP- collagen I carboxyterminal peptide